Streamlining Anthem (Elevance Health) Xtandi Prior Authorization

Navigating the Anthem (Elevance Health) Xtandi prior authorization process requires precise understanding of payer-specific requirements and submission channels. Klivira automates critical steps to accelerate approvals for this high-volume medication.

For revenue cycle directors and prior authorization coordinators, managing specialty drug PAs, such as for Xtandi, presents significant administrative burden. Anthem-licensed plans, operating under the Elevance Health umbrella, have distinct pathways and criteria that demand efficient, accurate submissions to ensure timely patient access to therapy.

Understanding Xtandi Prior Authorization with Anthem

Xtandi (enzalutamide) is an oral medication frequently prescribed for prostate cancer, often requiring prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans. For Anthem-licensed plans, the PA process for Xtandi is primarily managed through CarelonRx, Elevance Health's in-house PBM, which dictates formulary, step therapy, and quantity limit requirements.

Key Submission Channels for Anthem Xtandi PAs

**Pharmacy Benefit:** For Xtandi, as an oral specialty medication, prior authorization typically routes through CarelonRx's provider PA system.
**ePA Integration:** Prescriber-initiated pharmacy benefit PAs can be submitted via industry-standard electronic prior authorization (ePA) platforms, including CoverMyMeds and Surescripts, which integrate with CarelonRx.
**Medical Benefit (Limited Scope):** While Xtandi is generally pharmacy benefit, some specialty drugs administered under the medical benefit are handled via Availity Essentials for Anthem-licensed plans, or potentially through Carelon for specific categories.
**X12 278 Transactions:** For medical benefit PAs, X12 278 transactions are accepted via clearinghouses, providing an electronic alternative to portal submissions.

Navigating Anthem's Utilization Management Policies for Xtandi

Anthem operating companies publish medical policies and clinical utilization management guidelines through provider sites accessible via Availity. For Xtandi, specific criteria related to diagnosis, previous therapies (step therapy), and clinical necessity are outlined in these policies, often referencing Anthem-developed or NCCN-compendium-based criteria. CarelonRx also maintains its own criteria for pharmacy benefit drugs.

Expediting Xtandi PA Decisions with Anthem

Turnaround times for Xtandi prior authorizations from Anthem are governed by state-specific regulations for commercial plans and by CMS-0057-F for Medicare Advantage and Medicaid managed-care plans, mandating 72-hour standard and 24-hour expedited decision timeframes. Klivira's automated workflows are designed to meet these critical deadlines by ensuring complete and accurate submissions from the outset.

Common Denial Factors and Appeal Pathways for Xtandi

**Medical Necessity / Insufficient Documentation:** Lack of comprehensive clinical documentation supporting the diagnosis or treatment plan.
**Step Therapy Not Completed:** Failure to demonstrate adherence to Anthem's required sequence of alternative therapies.
**Non-Formulary:** Prescribing a non-preferred drug when a formulary alternative is available without appropriate justification.
**Site-of-Service Mismatch:** While less common for oral Xtandi, certain specialty drugs face denials due to inappropriate administration settings.
**Appeal Process:** Denials for pharmacy benefit drugs like Xtandi typically follow the standard Anthem operating-company appeals process, with peer-to-peer review options available.

Klivira's Approach to Anthem Xtandi PA Automation

Klivira integrates directly with EMR systems and connects with payer portals and ePA partners like CoverMyMeds and Surescripts to automate the Anthem Xtandi prior authorization workflow. Our platform streamlines data extraction, intelligently populates submission forms, and tracks real-time status updates, significantly reducing manual effort and improving decision turnaround times for specialty medications.

Frequently asked questions

How is Xtandi prior authorization submitted to Anthem (Elevance Health)?

For Anthem-licensed plans, Xtandi prior authorization, as an oral pharmacy benefit medication, is primarily submitted through CarelonRx's provider PA system. Electronic submissions can also be made via ePA platforms like CoverMyMeds and Surescripts, which integrate with CarelonRx.

Which PBM handles Xtandi prior authorization for Anthem-licensed plans?

CarelonRx, rebranded from IngenioRx, is the in-house Pharmacy Benefit Manager (PBM) that serves Anthem-licensed plans and manages prior authorizations for pharmacy benefit drugs like Xtandi.

Where can I find Anthem's medical policies and criteria for Xtandi?

Anthem operating companies publish medical policies and clinical utilization management guidelines through their provider sites, typically accessed via Availity. For Xtandi, these policies will outline specific medical necessity criteria and formulary requirements.

What are common reasons for Xtandi prior authorization denials from Anthem?

Common denial reasons for Xtandi from Anthem include insufficient documentation of medical necessity, failure to complete required step therapy protocols, or prescribing a non-formulary drug without adequate clinical justification. Site-of-service mismatch can also be a factor for other specialty drugs.

What are the typical turnaround times for Xtandi prior authorization decisions from Anthem?

Turnaround times vary by plan type and state. For Medicare Advantage and Medicaid managed-care plans, Anthem must adhere to CMS-0057-F requirements, mandating 72-hour standard and 24-hour expedited decision timeframes. Commercial plan timeframes are dictated by state insurance regulations.